CA2372511C - Polypeptides secretes et transmembranaires et acides nucleiques les codant - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques les codant Download PDF

Info

Publication number
CA2372511C
CA2372511C CA2372511A CA2372511A CA2372511C CA 2372511 C CA2372511 C CA 2372511C CA 2372511 A CA2372511 A CA 2372511A CA 2372511 A CA2372511 A CA 2372511A CA 2372511 C CA2372511 C CA 2372511C
Authority
CA
Canada
Prior art keywords
nucleic acid
polypeptide
acid sequence
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2372511A
Other languages
English (en)
Other versions
CA2372511A1 (fr
Inventor
Avi J. Ashkenazi
Kevin P. Baker
David Botstein
Luc Desnoyers
Dan L. Eaton
Napoleone Ferrara
Sherman Fong
Wei-Qiang Gao
Hanspeter Gerber
Mary E. Gerritsen
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Ivar J. Kljavin
Jennie P. Mather
Mary A. Napier
James Pan
Nicholas F. Paoni
Margaret Ann Roy
Timothy A. Stewart
Daniel Tumas
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/fr
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/fr
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/fr
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/fr
Priority claimed from PCT/US1999/028301 external-priority patent/WO2000032776A2/fr
Priority claimed from PCT/US1999/028565 external-priority patent/WO2000037638A2/fr
Priority claimed from PCT/US2000/000219 external-priority patent/WO2000053753A2/fr
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/fr
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/fr
Priority claimed from PCT/US2000/004414 external-priority patent/WO2001004311A1/fr
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/007377 external-priority patent/WO2001019991A1/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/013358 external-priority patent/WO2000075317A2/fr
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/fr
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2372511A1 publication Critical patent/CA2372511A1/fr
Application granted granted Critical
Publication of CA2372511C publication Critical patent/CA2372511C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)

Abstract

L'invention concerne des nouveaux polypeptides ainsi que des molécules d'acides nucléiques codant ces polypeptides. Elle concerne encore des vecteurs et des cellules hôtes comprenant ces séquences d'acides nucléiques, des molécules polypeptidiques chimères comprenant les polypeptides de l'invention fusionnés à des séquences polypeptides hétérologues, des anticorps se liant aux polypeptides de l'invention, ainsi que des procédés de production desdits polypeptides.
CA2372511A 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant Expired - Lifetime CA2372511C (fr)

Applications Claiming Priority (45)

Application Number Priority Date Filing Date Title
US13969599P 1999-06-15 1999-06-15
US60/139,695 1999-06-15
US14507099P 1999-07-20 1999-07-20
US60/145,070 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60/145,698 1999-07-26
US14939699P 1999-08-17 1999-08-17
US60/149,396 1999-08-17
USPCT/US99/20111 1999-09-01
PCT/US1999/020111 WO2000012708A2 (fr) 1998-09-01 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
PCT/US1999/020594 WO2000015666A2 (fr) 1998-09-10 1999-09-08 Compositions et methodes de traitement des tumeurs
USPCT/US99/20594 1999-09-08
PCT/US1999/021090 WO2000015796A2 (fr) 1998-09-16 1999-09-15 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US1999/021547 WO2000015797A2 (fr) 1998-09-17 1999-09-15 Compositions et methodes de traitement des maladies relatives au syteme immunitaire
USPCT/US99/21547 1999-09-15
USPCT/US99/21090 1999-09-15
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
USPCT/US99/28313 1999-11-30
PCT/US1999/028301 WO2000032776A2 (fr) 1998-12-01 1999-12-01 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US99/28301 1999-12-01
USPCT/US99/28565 1999-12-02
PCT/US1999/028565 WO2000037638A2 (fr) 1998-12-22 1999-12-02 Methodes permettant d'inhiber la croissance de cellules neoplasiques
US16949599P 1999-12-07 1999-12-07
US60/169,495 1999-12-07
PCT/US2000/000219 WO2000053753A2 (fr) 1999-03-08 2000-01-05 Activation ou inhibition de l'angiogenese et de la cardiovascularisation
USPCT/US00/00219 2000-01-06
USPCT/US00/04342 2000-02-18
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US2000/004341 WO2000053756A2 (fr) 1999-03-08 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/04341 2000-02-18
PCT/US2000/004414 WO2001004311A1 (fr) 1999-07-07 2000-02-22 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04414 2000-02-22
USPCT/US00/05601 2000-03-01
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/05841 2000-03-02
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
PCT/US2000/007377 WO2001019991A1 (fr) 1999-09-15 2000-03-20 Compositions et techniques permettant de traiter des maladies d'origine immunologique
USPCT/US00/07377 2000-03-20
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
USPCT/US00/08439 2000-03-30
PCT/US2000/013358 WO2000075317A2 (fr) 1999-06-09 2000-05-15 Compositions et methodes de traitement de tumeur
USPCT/US00/13358 2000-05-15
USPCT/US00/13705 2000-05-17
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant

Publications (2)

Publication Number Publication Date
CA2372511A1 CA2372511A1 (fr) 2000-12-21
CA2372511C true CA2372511C (fr) 2011-11-22

Family

ID=36028885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2372511A Expired - Lifetime CA2372511C (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant

Country Status (5)

Country Link
EP (1) EP1208195A2 (fr)
JP (6) JP2003529324A (fr)
AT (2) ATE449109T1 (fr)
CA (1) CA2372511C (fr)
WO (1) WO2000077037A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2002016611A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Polypeptides d'interleukine-22, acides nucleiques codant pour lesdits polypeptides et methode permettant de traiter les affections pancreatiques
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1591452B1 (fr) * 1999-03-23 2008-05-21 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6566078B1 (en) 1999-10-28 2003-05-20 Agensys, Inc. 36P6D5: secreted tumor antigen
AU2253301A (en) 1999-12-03 2001-06-12 Zymogenetics Inc. Human cytokine receptor
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
CA2395443A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Procedes et substances relatifs a des polypeptides de type facteur de croissance de cellules souches et a des polynucleotides
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001273150A1 (en) * 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030012788A1 (en) 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
JP2004527210A (ja) 2000-08-02 2004-09-09 ザ ジョンズ ホプキンス ユニバーシティー 内皮細胞発現パターンの評価法
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
WO2002051868A2 (fr) * 2000-12-23 2002-07-04 Kirin Beer Kabushiki Kaisha Procedes et materiaux concernant des polypeptides et des polynucleotides de type facteur de croissance de cellules souches
WO2002064769A1 (fr) * 2001-02-15 2002-08-22 Shionogi & Co., Ltd. Nouveau marqueur de maladies
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
WO2002072811A2 (fr) * 2001-03-13 2002-09-19 Bayer Aktiengesellschaft Regulation de la proteine de type lyase prenylcysteine humaine
CA2439961A1 (fr) 2001-03-27 2002-10-03 Zymogenetics, Inc. Recepteur de cytokine humaine
WO2002097110A2 (fr) * 2001-05-25 2002-12-05 Amgen, Inc. Molecules de marqueur endothelial tumoral 7$g(a) et utilisations associees
WO2003013580A1 (fr) * 2001-08-03 2003-02-20 Genset S.A. Traitement des troubles du metabolisme a l'aide d'agonistes et d'antagonistes xidatine
US20030219823A1 (en) * 2001-09-07 2003-11-27 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20050084841A1 (en) * 2002-01-29 2005-04-21 Orit Segev Isle gene and its association with osteoarthritis and other bone and cartilage disorders expression products derived therefrom and uses thereof
AU2003223344B9 (en) 2002-03-22 2009-07-16 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of using in inflammation
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2007525438A (ja) 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
SG10201405231YA (en) 2003-05-06 2014-09-26 Nippon Kogaku Kk Projection optical system, exposure apparatus, and exposure method
US7348575B2 (en) 2003-05-06 2008-03-25 Nikon Corporation Projection optical system, exposure apparatus, and exposure method
JP2007520217A (ja) * 2004-01-27 2007-07-26 コンピュゲン ユーエスエイ，インク． 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
KR20070036089A (ko) 2004-07-02 2007-04-02 제넨테크, 인크. 비호지킨 림프종의 치료 방법 및 치료 조성물
EP1781824A2 (fr) * 2004-08-25 2007-05-09 Genentech, Inc. Nouvelles disruptions geniques; compositions et methodes y relatives
AU2005299809B2 (en) 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
US6057435A (en) * 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
NZ503343A (en) * 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
AU4320499A (en) * 1998-06-02 1999-12-20 Eli Lilly And Company Angiopoietin related gene sequence scarface 1
CA2314004A1 (fr) * 1998-10-09 2000-04-20 Incyte Pharmaceuticals, Inc. Genes de remodelage de matrice

Also Published As

Publication number Publication date
ATE448246T1 (de) 2009-11-15
JP2006025795A (ja) 2006-02-02
WO2000077037A3 (fr) 2002-02-28
JP2003529324A (ja) 2003-10-07
CA2372511A1 (fr) 2000-12-21
JP2006051031A (ja) 2006-02-23
JP2006051032A (ja) 2006-02-23
JP2006061156A (ja) 2006-03-09
ATE449109T1 (de) 2009-12-15
JP2006068006A (ja) 2006-03-16
WO2000077037A2 (fr) 2000-12-21
EP1208195A2 (fr) 2002-05-29

Similar Documents

Publication Publication Date Title
CA2372511C (fr) Polypeptides secretes et transmembranaires et acides nucleiques les codant
US7087738B2 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7135334B2 (en) PRO20044 nucleic acids
US20030104558A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20070105191A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001004311A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US7033825B2 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060246540A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020177165A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding
US20020192209A1 (en) Methods and compositions for inhibiting neoplastic cell growth
US6974689B1 (en) Nucleic acid encoding PRO211 polypeptides
US20040147017A1 (en) Secreted and trasmembrane polypeptides and nucleic acids encoding the same
US6894148B2 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1953173A1 (fr) Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
CA2585822A1 (fr) Marqueur polypeptidique pro19628 pour tumeur du sein, du rectum, du colon ou du poumon et acide nucleique encodant
US20100261217A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040137561A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2501815A1 (fr) Compositions et methodes de traitement de tumeur

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200522